DMARDS Info

Question 1

Abatacept

Answer 1

Drug Type: Recombinant fusion protein
Target: MHC receptors
Mechanism of action: Binds to MHC receptors on antigen-­presenting cells to block T cell activation

Question 2

Anakinra

Answer 2

Drug Type: Receptor antagonist
Target: IL-­1 receptors
Mechanism of action:Binds to IL-­1 receptors to block IL-­1 proinflammatory signaling pathway

Question 3

Infliximab

Answer 3

Drug Type: Recombinant chimeric human-­murine monoclonal antibody
Target: TNF-­α
Mechanism of action:Binds to TNF-­α. The drug has higher affinity to TNF-­α than the receptor, so TNF-­α could dissociate from its receptor

Question 4

Adalimumab

Answer 4

Drug Type: Recombinant monoclonal antibody
Target: TNF-­α
Mechanism of action:Binds to TNF-­α and inhibits the interactions of this cytokine to p55 and p75 receptors

Question 5

Etanercept

Answer 5

Drug Type: Recombinant fusion protein
Target: TNF-­α
Mechanism of action:Competes with TNF-­α receptor for the binding of TNF-­α

Question 6

Tocilizumab

Answer 6

Drug Type: Humanized monoclonal antibody
Target: IL-­6 receptors
Mechanism of action:Binds to IL-­6 receptors to inhibit the association between the receptor and IL-­6

Question 7

Sulfasalazine

Answer 7

Drug Type: Combination of sulfapyridine and 5-­salicylic acid
Target: Unknown
Mechanism of action:Modulates B cell response and angiogenesis

Question 8

Methotrexate

Answer 8

Drug Type: Folate antagonist
Target: Dihydrofolate reductase
Mechanism of action:Inhibits dihydrofolate reductase activity, resulting in adenosine-­dependent inhibition of inflammation

Question 9

Canakinumab

Answer 9

Drug Type: Monoclonal IgG antibody
Target: IL-­1β
Mechanism of action:Binds to IL-­1β with high affinity to inhibit IL-­1β and receptor association